1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Clinical Supply Management
  6.  » Risk Mitigation in Direct-to-Patient Clinical Trials

Risk Mitigation in Direct-to-Patient Clinical Trials

Summary: Although decentralized clinical trials (DCTs) have been on the rise for many years, the COVID-19 pandemic accelerated growth in this area, especially in direct-to-patient (DTP) supply models. DCTs and DTP supply carry increased risks that can be difficult to navigate, but anticipating those risks and developing a strategy to mitigate them can help ensure studies stay on track and within budget.

Click here to view the article